NCT03041259: An ongoing trial by Reven Pharmaceuticals, Inc.
This trial is ongoing. It must report results 2 years, 5 months from now.
|Full entry on ClinicalTrials.gov||NCT03041259|
|Title||A Phase I/IIa Dose-Escalation Study Evaluating the Safety, Tolerability and Efficacy of Rejuveinix in Combination With Standard Interventional Therapy for Critical Limb Ischemia Patients|
|ACT or pACT?||This is what FDAAA officially calls an "Applicable Clinical Trial"|
|Start date||Jan. 31, 2020|
|Completion date||Jan. 31, 2022|
|Required reporting date||Jan. 31, 2023, midnight|
|Actual reporting date||None|
|Date last checked at ClinicalTrials.gov||Aug. 10, 2020|